Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab

Locally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristancho, Cagney, Riano, Ivy, Guareras-Paredes, Daniel, Park, Robin, Seetharaman, Kala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290116/
https://www.ncbi.nlm.nih.gov/pubmed/32542127
http://dx.doi.org/10.7759/cureus.8072
_version_ 1783545601147797504
author Cristancho, Cagney
Riano, Ivy
Guareras-Paredes, Daniel
Park, Robin
Seetharaman, Kala
author_facet Cristancho, Cagney
Riano, Ivy
Guareras-Paredes, Daniel
Park, Robin
Seetharaman, Kala
author_sort Cristancho, Cagney
collection PubMed
description Locally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, anti-PD-1 antibodies represent a novel immunotherapeutic strategy in cancer. We present a case of an advanced cSCC not amenable to surgical resection, who experienced dramatic improvement following treatment with the programmed cell death protein 1 receptor (PD-1) inhibitor pembrolizumab as an immunotherapeutic strategy.
format Online
Article
Text
id pubmed-7290116
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-72901162020-06-14 Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab Cristancho, Cagney Riano, Ivy Guareras-Paredes, Daniel Park, Robin Seetharaman, Kala Cureus Dermatology Locally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, anti-PD-1 antibodies represent a novel immunotherapeutic strategy in cancer. We present a case of an advanced cSCC not amenable to surgical resection, who experienced dramatic improvement following treatment with the programmed cell death protein 1 receptor (PD-1) inhibitor pembrolizumab as an immunotherapeutic strategy. Cureus 2020-05-12 /pmc/articles/PMC7290116/ /pubmed/32542127 http://dx.doi.org/10.7759/cureus.8072 Text en Copyright © 2020, Cristancho et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Cristancho, Cagney
Riano, Ivy
Guareras-Paredes, Daniel
Park, Robin
Seetharaman, Kala
Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
title Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
title_full Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
title_fullStr Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
title_full_unstemmed Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
title_short Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
title_sort complete resolution of a large, locally-advanced cutaneous squamous cell carcinoma with the immune-modulating pd-1 inhibitor pembrolizumab
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290116/
https://www.ncbi.nlm.nih.gov/pubmed/32542127
http://dx.doi.org/10.7759/cureus.8072
work_keys_str_mv AT cristanchocagney completeresolutionofalargelocallyadvancedcutaneoussquamouscellcarcinomawiththeimmunemodulatingpd1inhibitorpembrolizumab
AT rianoivy completeresolutionofalargelocallyadvancedcutaneoussquamouscellcarcinomawiththeimmunemodulatingpd1inhibitorpembrolizumab
AT guarerasparedesdaniel completeresolutionofalargelocallyadvancedcutaneoussquamouscellcarcinomawiththeimmunemodulatingpd1inhibitorpembrolizumab
AT parkrobin completeresolutionofalargelocallyadvancedcutaneoussquamouscellcarcinomawiththeimmunemodulatingpd1inhibitorpembrolizumab
AT seetharamankala completeresolutionofalargelocallyadvancedcutaneoussquamouscellcarcinomawiththeimmunemodulatingpd1inhibitorpembrolizumab

Ejemplares similares